PRESS RELEASE

Notice regarding appointment of new External Director

Tokyo, Japan and London, UK, 1 March 2019 – Sosei Group Corporation ("the Company"; TSE: 4565), announces that at the Board of Directors meeting held on 28 February 2019, the Company decided, based on the resolution of the Nomination Committee, to submit the following candidate as a new External Director for approval at the 29th Ordinary General Meeting of Shareholders to be held on 27 March 2019.

- Mr. Noriaki Nagai

1. Purpose of appointing new External Director

To enhance the supervisory function of the Board of Directors, by leveraging his deep expertise and experience on compliance and corporate governance, with the aim of enhancing our overall corporate governance system.

2. New appointed External Director candidate

Name	Professional history	
Mr. Noriaki Nagai (born 12/1/1957)	Apr. 1981	Joined the Underwriting Dept. of Nomura Securities, Co., Ltd. (NSC)
	Sep. 1998	Managing Director, Head of European Administration Division of Nomura International plc, London
	Jun. 2000	General Manager, Legal Dept., NSC
	Apr. 2006	Member of Board of Executive Officers, Head of Corporate Planning and Legal Dept., Nomura Holdings, Inc. (NHI) and NSC
	Apr. 2010	Executive Managing Director, NSC
	Apr. 2011	Chief Legal Officer, Senior Corporate Managing Director, NHI Senior Corporate Managing Director, NSC
	Jun. 2013	Non-executive Director, Japan Securities Depository Center, Inc.
	Jun. 2013	Non-executive Director, Japan Securities Clearing Corporation
	Apr. 2014	Deputy Chief of Staff and Chief Legal Officer, Senior Corporate Managing Director, NHI and NSC
	Apr. 2015	Professor of Business Law, Doshisha University (to the present)

3. Current directors seeking to be reappointed

Shinichi Tamura, Representative Executive Officer
Tomohiro Tohyama, External Director
Julia Gregory, External Director
Kuniaki Kaga, External Director
David Roblin, External Director

– Ends –

PRESS RELEASE

About Sosei Heptares

We are an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications. Its leading clinical programs include partnered candidates aimed at the symptomatic treatment of Alzheimer's disease (with Allergan) and next generation immuno-oncology approaches to treat cancer (with AstraZeneca). Our additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK and Zurich, Switzerland.

"Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit https://www.soseiheptares.com/
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco

Enquiries:

Sosei Heptares
Investor Relations and Corporate Communications
Shinichiro Nishishita, Yu Okada
+81 (0)3 5210 3399
IR@SoseiHeptares.com

Citigate Dewe Rogerson (for international media)
Mark Swallow, David Dible
+44 (0)20 7638 9571
SoseiHeptares@citigatedewerogerson.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.